Antimalarial medication multi-drug resistant "P. falciparum". It is a very potent blood schizonticide with a long half-life. It is thought to act by forming toxic heme complexes that damage parasitic food vacuoles. Mefloquine is effective in prophylaxis and for acute therapy. It is now used solely for the prevention of resistant strains of "P. falciparum" (usually combined with Artesunate) despite being effective against "P. vivax", "P. ovale" and "P. marlariae". Chloroquine/proguanil or sulfa drug-pyrimethamine combinations should be used in all other plasmodia infections. The major commercial manufacturer of mefloquine-based malaria treatment is Roche Pharmaceuticals, which markets the drug under the trade name
International Association for the Treatment of Sexual Offenders the context of their family, school, and other social systems in order to fully understand and decide the treatment and care for the juvenile. Another important element to keep in mind when choosing a treatment is to base it on a developmental perspective, which means it is sensitive to developmental change. This is necessary because during adolescence the brain is not fully developmental and is subjected to change. During assessment and treatment focus not only on the risks of the youths but also their strengths. Keep in mind that sexual interests of youth do change over adolescence and sexual orientation